Pfenex will engineer production strains, using its Pseudomonas fluorescens organism, broad tool box, and high throughput robotically enabled strain screening platform, to express MedImmune lead molecules. Pfenex claims that it routinely can go from DNA to an identified production strain within 8 weeks. MedImmune will carry forward preclinical and clinical development.
MedImmune senior vice president of biopharmaceutical development, Gail Wasserman said "Pfenex's scientific approach to strain development and protein expression is robust and aligned with the way we work at MedImmune."
The Pfenex system utilizes defined development and production media that are free of animal proteins. The platform has been accepted by US and international regulatory agencies in multiple human clinical trials up to Phase III currently in progress.
Posted by Bruce Lehr May 12th 2011.